Serum Lp-PLA2 Level Predicting Coronary Artery Lesions in Children with Kawasaki Disease


  • Xiong Zhang Department of Laboratory, First People’s Hospital of Xianyang City, Xianyang, Shaanxi Province, China
  • Ya-Wang Shao Department of Pediatrics, First People’s Hospital of Xianyang City, Xianyang, Shaanxi Province, China
  • Ya-Lan Zhang Department of Laboratory, First People’s Hospital of Xianyang City, Xianyang, Shaanxi Province, China
  • Yi Liu Department of Laboratory, First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, China



Kawasaki disease, coronary artery lesions, lipoprotein associated phospholipase A2


Background: Kawasaki disease (KD) is an inflammatory disease associated with coronary vasculitis in children. In this study, we explored the correlation between Lipoprotein associated phospholipase A2 (Lp-PLA2) and coronary artery lesions (CAL) in children with KD.

Methods: Ninety-three children with KD were divided into a normal coronary artery (NCA, 54 cases) group and coronary artery lesions (CAL, 39 cases) group, according to the results of echocardiography. Another 42 healthy children were selected as the control group. The serumal levels of Lp-PLA2, Interferon-γ(IFN-γ) and Interleukin-6 (IL-6) were determined by using an enzyme-linked immunosorbent assay. In addition, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level were analyzed. The left main coronary artery (LMCA), diameters of left anterior descending coronary artery (LADC), right proximal coronary artery (PRCA), and carotid intima-media thickness (IMT) were obtained by color Doppler ultrasound. The correlation between the above indexes and KD was analyzed.

Results: The levels of white blood cell counts (WBC), ESR, CRP, IFN-γ, IL-6 and Lp-PLA2 as well as IMT were significantly increased in KD children (P < 0.05), and the levels of CRP, IFN-γ, IL-6 and Lp-PLA2 as well as IMT in the CAL group increased more significantly (P < 0.05). An increasing trend also has been described in the diameters of LMCA, LADC and PRCA for KD children with CAL compared with with NCA. The results of logistic regression analysis showed that the elevated levels of CRP, IFN-γ, IL-6 and Lp-PLA2 were independent risk factors for KD with CAL. Correlation analysis showed that Lp-PLA2 level was positively correlated with the levels of IFN-γ, IL-6 and CRP in CAL group and NCA group (respectively, all P < 0.01). In addition, a similar correlation was also described between Lp-PLA2 level and the diameters of LMCA, LADC and PRCA in CAL group (respectively, all P < 0.01).

Conclusion: Lp-PLA2 may participate in the pathological mechanism of KD. Detection of the serum Lp-PLA2 level can be used in the diagnosis of KD disease and the assessment of coronary artery lesions in KD children.


Acosta S, Taimour S, Gottsater A, et al. 2017. Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study. Atherosclerosis. 262: 14-18.

Amano S, Hazama F, Hamashima Y. 1979. Pathology of Kawa-saki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ. J 43: 633-643.

Biscetti F, Nardella E, Bonadia N, et al. 2019. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc Diabetol. 1:74.

Chen AD, Wang CL, Qin Y, et al. 2017. The effect of Danshen extract on lipoprotein-associated phospholipase A2 levels in patients with stable angina pectoris: study protocol for a randomized controlled trial - the DOLPHIN study. Trials. 18: 606.

Choi WG, Prasad M, Lennon R, et al. 2018. Chronic darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: A randomized-controlled study. Coron Artery Dis. 2:104-113.

Hedrich CM, Schnabel A, Hospach T. 2018. Kawasaki Disease. Front Pediatr. 6: 198.

Herrmann J, Mannheim D, Wohlert C, et al. 2009. Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 23:2930–8.

Huang YH, Hsu YW, Lu HF, et al. 2016. Interferon-gamma Genetic Polymorphism and Expression in Kawasaki Disease. Medicine (Baltimore). 17:e3501.

Kobayashi N, Mori M, Kobayashi Y, et al. 2004. Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease. Mod Rheumatol. 14:447-452.

Kobayashi T, Inoue Y, Takeuchi K, et al. 2006. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 22:2606-2612.

Kolodgie FD, Burke AP, Skorija KS, et al. 2006. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 11:2523-9.

Lehtinen L, Vainio P, Wikman H, et al. 2017. PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. J Pathol Clin Res. 2:123-138.

Leung DY, Geha RS, Newburger JW. et al. 1986. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 164:1958-1972.

Liu XQ, Huang GY, Liang XC, et al. 2007. The study of vascular lesion using ultrasound in children with a history of Kawasaki disease. Zhonghua Yi Xue Za Zhi. 30: 2117-20.

Macphee CH, Nelson J, Zalewski A. 2006. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2: 154-161.

Matsubara T, Ichiyama T, Furukawa S. 2005. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin. Exp. Immunol. 141: 381-387.

McCrindle BW, Cifra B. 2018. The role of echocardiography in Kawasaki disease. Int J Rheum Dis. 21:50-55.

McCrindle BW, Rowley AH, Newburger JW, et al. 2017. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 17: e927- e999.

Meena RS, Rohit M, Gupta A, et al. 2014. Carotid intima-media thickness in children with Kawasaki disease. Rheumatol Int, 8: 1117-1121.

Menikou S, Langford PR, Levin M. 2019. Kawasaki disease: the role of immune complexes revisited. Front Immunol. 10: 1156.

Munzel T, Gori T. 2009. Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur Heart J. 23: 2829-2831.

Nakamura Y, Yashiro M, Uehara R, et al. 2010. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J. Epidemiol. 20: 302-307.

Naoe S, Takahashi K, Masuda H, et al. 1991. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 41:785-797.

Noto N, Okada T, Karasawa K, et al. 2009. Age-related acceleration of endothelial dysfunction and subclinical atherosclerosis in subjects with coronary artery lesions after Kawasaki disease. Pediatr Cardiol. 30: 262-268.

Poznyak AV, Zhang DW, Orekhova V, et al. 2020. A brief overview of currently used atherosclerosis treatment approaches targeting lipid metabolism alterations. Am J Cardiovasc Dis. 2:62–71.

Siddiqui MK, Kennedy G, Carr F, et al. 2018. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia. 6:1344-1353.

Takahashi K, Oharaseki T, Yokouchi Y, et al. 2007. Kawasaki disease arteritis and polyarteritis nodosa. Pathol Case Rev. 12:193-199.

Tsuda E, Tsujii N, Kimura K, et al. 2017. Distribution of Kawasaki Disease coronary artery aneurysms and the relationship to coronary artery diameter. Pediatr Cardiol. 38:932–940.

Wang HL, Zhang N, Li GR, et al. 2019. Proinflammatory cytokine IFN-γ, lncRNA BANCR and the occurrence of coronary artery disease. Life Sciences. 231:116510.

Wang Y, Qian SY, Yuan Y, et al. 2020. Do cytokines correlate with refractory Kawasaki disease in children? Clinica Chimica Acta. 506:222–227.

Xue M, Wang J. 2020. Utility of color Doppler echocardiography combined with clinical markers in diagnosis and prediction of prognosis of coronary artery lesions in Kawasaki disease. Exp Ther Med. 19:2597-2603.

Yandie Li, Qi Zheng, Lixia Zou, et al. 2019. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr Rheumatol Online J. 1:1.

Zalewski A, Macphee C. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 5: 923-931.

Zhang DF, Liu LJ, Huang XP, et al. 2020. Insights Into Coronary Artery Lesions in Kawasaki Disease. Front Pediatr. 8:493.



How to Cite

Zhang, X., Ya-Wang Shao, Ya-Lan Zhang, & Yi Liu. (2021). Serum Lp-PLA2 Level Predicting Coronary Artery Lesions in Children with Kawasaki Disease. The Heart Surgery Forum, 24(4), E611-E618.